Geron (NASDAQ:GERN) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Geron (NASDAQ:GERN) in a report issued on Wednesday morning,Benzinga reports.

A number of other brokerages have also weighed in on GERN. Stifel Nicolaus cut their price objective on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price target on shares of Geron in a research report on Wednesday. Barclays reiterated an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. Finally, Scotiabank dropped their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Trading Up 10.6 %

Shares of Geron stock opened at $1.77 on Wednesday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -5.53 and a beta of 0.53. The business has a 50-day moving average price of $2.69 and a 200-day moving average price of $3.62. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a twelve month low of $1.46 and a twelve month high of $5.34.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Equities research analysts anticipate that Geron will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

Large investors have recently bought and sold shares of the business. RTW Investments LP bought a new position in Geron in the third quarter worth approximately $200,268,000. Nvest Financial LLC bought a new position in Geron in the fourth quarter worth approximately $693,000. Janus Henderson Group PLC raised its stake in Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock worth $102,193,000 after buying an additional 13,163,889 shares in the last quarter. Barclays PLC raised its stake in Geron by 114.9% in the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after buying an additional 694,931 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Geron in the third quarter worth approximately $1,102,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.